An investment firm with offices in the USA and Europe manages focused private equity funds for family offices and high-net worth individuals. The firm seeks to transform SMEs with local traction to global front-runners. Their typical investment size is $1 M – 20 M. They are looking to make 4 new investments in the next year, and are currently focused on OTM medical technology.
The firm is opportunistic and will consider deals across the life sciences board, but is currently focused on medical technology, industrial processes, materials, HCIT and digital health with high tech underpinnings, and food production, distribution, and transformation.
The firm desires an experienced, passionate team of entrepreneurs with international experience, capable of building a fast growing global business. They do not invest in start ups. They look to acquire 20-80% equity in SME’s with $3-5 M in revenue, or fast growing companies that will be generating revenue within a year with all regulatory barriers cleared. They require a clear, scalable path to globalization. The firm pursues a 60-day due diligence period when considering a deal.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment